Prolaktinoma

01Pathophysiology

Prolactinomas arise from lactotroph cells in the anterior pituitary gland. These are the single most common type of functioning pituitary adenoma. The tumor autonomously produces prolactin, bypassing the normal regulatory mechanisms that keep prolactin secretion in check.

Under normal physiology, prolactin is the only anterior pituitary hormone that is under tonic inhibitory control. Dopamine, released from the tuberoinfundibular pathway in the hypothalamus, travels down the pituitary stalk and binds to D2 receptors on lactotroph cells, continuously suppressing prolactin release. This is why any process that disrupts the pituitary stalk (trauma, compression by a non-functioning adenoma, infiltrative disease) can cause hyperprolactinemia through loss of dopamine inhibition, a concept known as the "stalk effect."

In a prolactinoma, the neoplastic lactotrophs secrete prolactin independently. The excess prolactin then causes downstream effects through two principal mechanisms:

First, hyperprolactinemia suppresses GnRH pulsatility from the hypothalamus. This leads to decreased LH and FSH secretion, resulting in hypogonadotropic hypogonadism. In women, this manifests as oligomenorrhea or amenorrhea and anovulatory infertility. In men, it causes low testosterone, reduced libido, and erectile dysfunction.

Second, prolactin directly stimulates mammary gland ductal epithelium, producing galactorrhea. This sign is far more commonly identified in premenopausal women because estrogen-primed breast tissue is more responsive to prolactin stimulation. In men, galactorrhea is rare because the breast tissue lacks sufficient estrogen priming.

A critical clinical point: women tend to present early with menstrual irregularities and galactorrhea, so their tumors are usually microadenomas (<10 mm). Men, lacking these early warning signs, present late with visual symptoms or headaches from macroadenomas (>=10 mm) that have grown large enough to compress the optic chiasm.

02Classification and Clinical Manifestation

By Sex

03Diagnostic Workup

Interpreting the prolactin level is the single most testable concept in this workup. The degree of prolactin elevation reliably correlates with tumor burden:

• Prolactin 25-100 ng/mL: Think drug-induced hyperprolactinemia, stalk effect, hypothyroidism, or microprolactinoma.

• Prolactin 100-200 ng/mL: Likely microprolactinoma.

• Prolactin >200 ng/mL: Strongly suggests macroprolactinoma. The higher the level, the larger the tumor.

• Prolactin >1,000 ng/mL: Giant prolactinoma until proven otherwise.

A critical trap involves the "hook effect" (also called the high-dose hook effect). In very large macroadenomas, the prolactin level can be so extraordinarily high that it saturates the immunoassay, producing a falsely normal or only mildly elevated result. If a patient has a large pituitary mass but a prolactin of only 40-80 ng/mL, the lab must be asked to perform serial dilutions of the sample. After dilution, the true prolactin level (often in the thousands) becomes apparent. Without recognizing this phenomenon, the clinician may misdiagnose the tumor as a non-functioning adenoma, leading to unnecessary surgery instead of medical therapy.

Another interpretive pitfall: a large pituitary mass with prolactin of 50-100 ng/mL (mildly elevated but not proportional to size) is more likely a non-functioning pituitary adenoma causing stalk effect rather than a true prolactinoma. The distinction matters because non-functioning adenomas require surgery, while prolactinomas respond to dopamine agonists.

After confirming the diagnosis biochemically, MRI of the sella turcica with gadolinium contrast is ordered to define the anatomy. MRI identifies tumor size, extension into the cavernous sinus, and proximity to or compression of the optic chiasm. For any macroadenoma, formal visual field testing is performed to document the baseline and monitor for improvement with treatment.

Before attributing hyperprolactinemia to a tumor, always exclude physiologic and pharmacologic causes first: pregnancy, hypothyroidism, renal failure, and dopamine-antagonist medications (antipsychotics like haloperidol and risperidone, antiemetics like metoclopramide).

04Management and Treatment

First-line therapy for nearly all prolactinomas is a dopamine agonist, not surgery. This is one of the highest-yield distinctions on the exam. Prolactinoma is the only pituitary adenoma where medical therapy is the primary treatment.

Cabergoline is the preferred dopamine agonist. It has superior efficacy in normalizing prolactin levels (achieves normalization in roughly 85-90% of patients), better tumor shrinkage profile, fewer side effects, and more convenient dosing (twice weekly instead of daily) compared to bromocriptine. Starting dose is 0.25 to 0.5 mg twice per week, with gradual uptitration every 4 weeks based on prolactin levels and clinical response.

Bromocriptine is the alternative agent, dosed at 1.25-2.5 mg daily and titrated up to 5-15 mg/day in divided doses. Its primary advantage is the longer safety record in pregnancy. For women actively planning conception, bromocriptine is typically preferred during the preconception period. Once pregnancy is confirmed, the dopamine agonist is generally discontinued for microprolactinomas (low risk of clinically meaningful growth). For macroadenomas in pregnancy, the decision is individualized because these tumors carry a higher risk of symptomatic enlargement due to estrogen-driven lactotroph stimulation.

Common side effects of dopamine agonists include nausea, orthostatic hypotension, and dizziness. These are minimized by starting at a low dose and taking the medication at bedtime with food. A rare but important long-term concern with high-dose cabergoline (as used in Parkinson disease) is cardiac valvular fibrosis, though the risk at the lower doses used for prolactinoma appears to be very low. Echocardiographic monitoring is recommended for patients on higher doses or prolonged therapy.

Transsphenoidal surgery is reserved for:

• Dopamine agonist intolerance or resistance (failure to normalize prolactin or shrink tumor despite adequate dosing)

• Pituitary apoplexy with acute neurological deterioration

• CSF leak from tumor erosion into the sphenoid sinus

• Patient preference (especially young women with microadenomas who wish to avoid lifelong medication)

Radiation therapy is a third-line option for aggressive or recurrent tumors that fail both medical and surgical management.

Monitoring during treatment involves serial prolactin levels every 3-6 months and repeat MRI at 3-6 months after starting therapy (earlier for macroadenomas with visual compromise). Visual field testing is repeated to document improvement.

After 2-3 years of successful treatment (normalized prolactin, significant tumor shrinkage), a trial of dopamine agonist withdrawal can be considered. Roughly one-third of patients will maintain normal prolactin levels off medication.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on prolactinoma questions is by selecting surgery as the initial treatment for a large pituitary mass. The reflex to operate on a tumor is strong, but prolactinoma is the exception: even large, invasive macroadenomas respond dramatically to dopamine agonist therapy, both in terms of prolactin normalization and tumor shrinkage. Surgery is never the first step unless there is acute visual compromise from apoplexy.

The second major trap is failing to recognize the hook effect. A vignette presenting a large sellar mass with a "mildly elevated" prolactin of 60 ng/mL is testing whether you will request serial dilutions before accepting that value at face value. Without dilution, the diagnosis shifts incorrectly to non-functioning adenoma, and the management changes from medical therapy to unnecessary surgery.

Third, always remember that any pituitary mass can cause mild hyperprolactinemia through stalk compression. The discriminator is proportionality: prolactin level should roughly match tumor size in a true prolactinoma. A large mass with low-grade prolactin elevation is stalk effect until proven otherwise.

Finally, for pregnancy-related questions: bromocriptine is the preferred agent when planning conception, microprolactinomas are generally safe during pregnancy (discontinue the dopamine agonist once pregnant), and the vignette will test whether you know that macroadenomas require closer monitoring because estrogen-driven growth during pregnancy can threaten vision.

The core competency being tested is the ability to integrate a prolactin level with imaging findings to arrive at the correct diagnosis, then to select medical therapy as the first-line intervention rather than defaulting to a surgical reflex.